Imatinib. Chronic myeloid leukaemia, first-line option: Favourable findings to be confirmed

Prescrire International

Volumn 12, Issue 68, 2003, Pages 216-218

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CYTARABINE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG ERUPTION; DRUG INDICATION; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; SIDE EFFECT; SKIN EXFOLIATION; SURVIVAL RATE; TREATMENT OUTCOME; VERTIGO; VOMITING; WATER RETENTION; ADULT; CHILD; COMPARATIVE STUDY; DRUG ANTAGONISM;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 0344877302     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Prescrire Editorial Staff "Chronic myeloid leukaemia" Prescrire Int 2003; 12 (64): 70.
2. Prescrire Editorial Staff "Imatinib for chronic myeloid leukaemia" Prescrire Int 2003; 12 (64): 49-52.
3. o (imatinib mesilate) - Expert report on the clinical documentation" 13 June 2002: 37 pages.
4. O'Brien S et al. "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia" N Engl J Med 2003; 348 (11): 994-1004.
5. o " 44th Annual meeting of the American Society of Hematology, December 2002; abstr. 346: 1 page.
6. o (imatinib mesilate) Expert Report on the pediatric clinical documentation" 13 June 2002: 28 pages.
7. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products - European Public Assessment Report (EPAR) "Glivec. Revision 2" 24 March 2003: 129 pages.
8. Dalziel K et al. "The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase" 28th March 2003. Website http://www.nice.org.uk consulted on 19 June 2003.